AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02118909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Study NCT00450814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00450814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00450814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Description: Given IV
Study NCT00450814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03878576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REFERENCE: white bread - BGL0 [RP]
Description: Determination of glycemic response after consumption of BGL0.
Study NCT03878576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST: b-glucan enriched bread - BGL2 [IP1]
Description: Determination of glycemic response after consumption of BGL0.
Study NCT04074317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAM9
Description: SC injection
Study NCT03878576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST: b-glucan enriched bread - BGL3 [IP2]
Description: Determination of glycemic response after consumption of BGL0.
Study NCT03878576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST: b-glucan enriched bread - BGL4 [IP3]
Description: Determination of glycemic response after consumption of BGL0.
Study NCT03478631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-nitrate dehydrated vegetable powder
Description: A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
Study NCT04074317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin + Pramlintide
Description: Separate SC injections
Study NCT03478631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-nitrate dehydrated vegetable powder
Description: A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
Study NCT03572465 — intervention group
Intervention type: DEVICE
Intervention: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)
Description: Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)
Study NCT02427334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest
Description: women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
Study NCT02427334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
Study NCT02427334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: women will receive oral placebo for 14 days starting from the 15th day of menstruation
Study NCT00804804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation and multiple rest
Description: To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
Study NCT04123405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine
Description: 600 mg tablet
Study NCT00933543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visonac PDT (MAL PDT)
Description: Cream application followed by illumination with red light.
Study NCT04074317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: SC injection
Study NCT00423891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
Study NCT02609022 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV-MG01
Description: 3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose.
Study NCT02609022 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
Study NCT03145441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb®
Description: CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
Study NCT03926234 — intervention group
Intervention type: OTHER
Intervention: Four-level Chinese Emergency triage scale
Description: a four-level category system, i.e. life-threatening (Level I), emergent (Level II), urgent (Level III) and semi-urgent (Level IV) . This system contains critical indicators (cardiac arrest, shock, and apnea), high risk indicators (ACS and DKA), single objective indicators (SBP, RR, HR, and SpO2) and MEWS (synthesis indicator). According to patients' health care problems, patients are rated by nurses into one of the four mentioned levels.
Study NCT02108821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
Study NCT01414335 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: amino acid composition
Description: one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
Study NCT01414335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
Study NCT02179996 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three vaccine injections DTP-pertussis-Hib
Description: DTP-pertussis-Hib injections at two, three, four months after birth
Study NCT02179996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two vaccine injections DTP-pertussis-Hib
Description: DTP-pertussis-Hib injections are administered at two and four months after birth
Study NCT00639834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1342
Description: One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
Study NCT05117411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA and pseudophakin cystoid edema
Description: Patients underwent OCT angiografia after cataract surgery
Study NCT01966965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIOLIN®
Description: PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
Study NCT01966965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEDAX
Description: AS SPECIFIED AT THE LEAFLET
Study NCT02886377 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood test of anti-AQP4 antibody
Description: Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-495 75mg
Description: CKD-495 75mg Tab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-495 150mg
Description: CKD-495 150mg Tab.
Study NCT02716272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
Study NCT00933543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream (placebo)
Description: Cream application followed by illumination with red light.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg
Description: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
Study NCT02716272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Description: Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
Study NCT01285856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hair and saliva samples
Description: Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling.
Study NCT00603278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X
Study NCT00603278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04943614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodex balance system
Description: BIODEX stability system (BIODEX Medical Systems Inc; Shirley, New York) offers a system that can deliver particular hip and ankle postural training strategy with external biofeedback as a monitor to enhance the reduced subclinical limitations of patients with diabetic neuropathy
Study NCT04943614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Description: balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program. Same duration treatment
Study NCT02389894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embol-X Embolic Protection Device
Description: per the manufacturer's instructions for use (IFU).
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide 100mg
Description: Rebamipide 100mg Tab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the CKD-495 75mg
Description: Placebo of the CKD-495 75mg Tab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of the CKD-495 75mg
Description: Placebo of the CKD-495 75mg Tab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of the CKD-495 75mg
Description: Placebo of the CKD-495 75mg Tab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the CKD-495 150mg
Description: Placebo of the CKD-495 150mg Tab.
Study NCT00933543 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PDT
Description: Photodynamic Therapy - Light dose 37 J/cm2
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of the CKD-495 150mg
Description: Placebo of the CKD-495 150mg Tab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of the CKD-495 150mg
Description: Placebo of the CKD-495 150mg Tab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Study NCT00933543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDT
Description: Photodynamic Therapy - Light dose 37 J/cm2
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the Rebamipide 100mg
Description: Placebo of the Rebamipide 100mg Tab
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of the Rebamipide 100mg
Description: Placebo of the Rebamipide 100mg Tab
Study NCT03437785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of the Rebamipide 100mg
Description: Placebo of the Rebamipide 100mg Tab
Study NCT04374890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP308
Description: 3 weeks of baseline followed by 2x3 weeks use of the test device
Study NCT01044082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: controlled cord traction
Description: In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
Study NCT01044082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical signs of placental separation
Description: Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
Study NCT03690388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
Study NCT03690388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
Study NCT03984422 — intervention group
Intervention type: OTHER
Intervention: Smartphone application
Description: use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
Study NCT02006277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib prototype microsphere 0.529 mg/mg
Description: Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
Study NCT02006277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.470 mg/mg
Description: Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
Study NCT02006277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.420 mg/mg
Description: Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
Study NCT02006277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib oral solution
Description: Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
Study NCT02006277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.529 mg/mg
Description: Subjects will receive a single 250-mg oral dose of crizotinib.
Study NCT02006277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.470 mg/mg
Description: Subjects will receive a single 250-mg oral dose of crizotinib.
Study NCT03794310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08 （1-day treatment）
Description: NPF-08 will be administered on the day of colonoscopy.
Study NCT02006277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.420 mg/mg
Description: Subjects will receive a single 250-mg oral dose of crizotinib.
Study NCT02006277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib capsule
Description: Subjects will receive a single 250-mg oral dose of crizotinib.
Study NCT02006277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib oral solution
Description: Subjects will receive a single 250-mg oral dose of crizotinib.
Study NCT03794310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08 （2-day split dose）
Description: NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
Study NCT03794310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moviprep（1-day treatment）
Description: Moviprep will be administered on the day of colonoscopy.
Study NCT04123405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to acetylcysteine
Study NCT04648865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537031
Description: Administered SC.
Study NCT04648865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT01466946 — intervention group
Intervention type: BEHAVIORAL
Intervention: semi-structured interviews
Description: Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin \& Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
Study NCT01666756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese herbal formulation PHY906
Description: Given PO
Study NCT01666756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT01666756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03482492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol iv
Study NCT01989806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)
Study NCT01666756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02984358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Animal protein based diet
Study NCT01989806 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)
Study NCT02984358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-nucleotide mycoprotein based diet
Study NCT02984358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-nucleotide mycoprotein based diet
Study NCT03715608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Description: The patients in the intervention group received psychological counseling and corresponding medication after the operation. Psychotherapy was based on the clinical expertise of the psychosocial specialist from Peking University Sixth Hospital, who selected the most appropriate plan for each patient.
Study NCT01110031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Anti-CD20 monoclonal antibody
Study NCT01294969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-4943A
Description: Once daily topical ocular allergy medication used for 7 days
Study NCT02888288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Intervention
Description: Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.
Study NCT02888288 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care includes enhanced ART adherence based on clinic protocols and monthly HIV teaching sessions prior to adolescent clinic.
Study NCT01169623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance
Description: 55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
Study NCT01169623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance
Description: 55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model